Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
Schoenfeld A, Lee S, de Speville B, Gettinger S, Hafliger S, Sukari A, Papa S, Rodriguez-Moreno J, Finckenstein F, Fiaz R, Catlett M, Chen G, Qi R, Masteller E, Gontcharova V, He K. Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer Discovery 2024, 14: 1389-1402. PMID: 38563600, PMCID: PMC11294887, DOI: 10.1158/2159-8290.cd-23-1334.Peer-Reviewed Original ResearchMetastatic non-small cell lung cancerAdverse eventsResistance to immune checkpoint inhibitorsPD-L1-negative tumorsPhase 2 multicenter studyLow tumor mutational burdenTreatment-emergent adverse eventsNon-small cell lung cancerTime of data cutoffRefractory to prior therapyPD-L1-negativeImmune checkpoint inhibitorsResistance to immunotherapyTumor mutational burdenCell lung cancerMultiple organ failurePotential treatment optionCheckpoint inhibitorsPrior therapyData cutoffPatient diedSystemic therapyMutational burdenSTK11 mutationsCardiac failure